Dementia

Lecanemab Linked to Lower Neuropsychiatric Symptoms in Alzheimer’s

by
Lecanemab Linked to Lower Neuropsychiatric Symptoms in Alzheimer's

TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional amyloid-beta positron emission tomography (PET) clearance. Key Findings 144 treated patients: The cohort included people with Alzheimer’s-related mild cognitive impairment or …

Read more

Tubulin Shifted Tau and Alpha-Synuclein Condensates Toward Microtubules

by
Tubulin Shifted Tau and Alpha-Synuclein Condensates Toward Microtubules

TL;DR: A 2026 study in Nature Communications reported that tubulin redirected Tau and alpha-synuclein condensates toward microtubule-building states, while tubulin loss pushed the same protein system toward toxic oligomers in cell models. Key Findings 36-hour shift: Tau and alpha-synuclein condensates formed stable high-molecular-weight oligomers and Tau:alpha-synuclein heterodimers after aging without tubulin. 10-micromolar tubulin: Adding tubulin …

Read more

Karyoptosis Linked Proteotoxic Stress to Neurodegeneration

by
Karyoptosis Linked Proteotoxic Stress to Neurodegeneration

TL;DR: A 2026 study in Nature Communications found that proteotoxic stress can push neurons into karyoptosis, a cell-death pathway marked by nuclear lamina breakdown, nuclear-material expulsion, and dementia-linked tissue signatures. Key Findings Karyoptosis was induced by protein-clearance stress: Blocking autophagic lysosomal clearance caused LaminB1 disruption, nuclear-shape loss, cytoplasmic nuclear material, and later cell death. p38-LaminB1 …

Read more

Brain-Derived Plasma pTau217 Better Predicted Near-Term Amyloid PET Progression

by
Brain-Derived Plasma pTau217 Better Predicted Near-Term Amyloid PET Progression

TL;DR: A 2026 ADNI analysis posted to medRxiv found that brain-derived plasma pTau217 better predicted near-term amyloid positron emission tomography (PET) positivity than total plasma pTau217 in cognitively unimpaired amyloid-negative participants. Key Findings 1,427 ADNI participants: Plasma NULISAseq biomarkers were measured across the broader Alzheimer’s Disease Neuroimaging Initiative sample. 529 cognitively unimpaired: The main prognostic …

Read more

Diclofenac and Naproxen Use Linked to Lower Dementia Prevalence in NACC Cohort

by
Diclofenac and Naproxen Use Linked to Lower Dementia Prevalence in NACC Cohort

TL;DR: A 2026 retrospective analysis posted to medRxiv linked diclofenac and naproxen use in the NACC cohort to lower dementia and Alzheimer disease prevalence, while diclofenac use was also associated with slower Montreal Cognitive Assessment (MoCA) cognitive-screening decline. Key Findings NACC cohort: The analysis used 47,165 National Alzheimer’s Coordinating Center participants with data collected from …

Read more

Japan Dementia Specialist Survey Protocol Mapped Anti-Amyloid Antibody Bottlenecks

by
Japan Dementia Specialist Survey Protocol Mapped Anti-Amyloid Antibody Bottlenecks

TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findings Nationwide specialist survey: The protocol targets board-certified dementia specialists in Japan, especially physicians trained for anti-amyloid antibody therapy. June 2026 data …

Read more

Alcohol Plus Stress Impaired Midlife Cognitive Flexibility in Mice

by
Alcohol Plus Stress Impaired Midlife Cognitive Flexibility in Mice

TL;DR: A 2026 mouse study in Alcohol: Clinical and Experimental Research found that chronic intermittent ethanol plus repeated forced-swim stress left mice drinking more alcohol months later and impaired reversal learning in midlife, alongside locus coeruleus signs of oxidative stress and weaker adrenergic autoregulation. Key Findings Persistent effects reached midlife: The experiment followed 55 C57BL/6J …

Read more

BCG Immunotherapy Altered CNS Immunity and Alzheimer’s Biomarkers

by
BCG Immunotherapy Altered CNS Immunity and Alzheimer's Biomarkers

TL;DR: A 2026 open-label study in Communications Medicine found that Bacillus Calmette-Guerin (BCG) immunotherapy changed cerebrospinal-fluid immune-cell responses and Alzheimer-related biomarkers in 23 older adults. Key Findings Small trial context: 2 related 1-year open-label trials enrolled 23 adults aged 55 or older at one academic medical center. BCG dosing was simple: Participants received 2 intradermal …

Read more

Brain-Derived p-tau217% Better Classified Alzheimer Pathology

by
Brain-Derived p-tau217% Better Classified Alzheimer Pathology

TL;DR: A 2026 preprint in medRxiv found that brain-derived p-tau217%, a blood marker designed to isolate central nervous system tau, classified Alzheimer disease pathology better than standard plasma p-tau217 in several Alzheimer cohorts. Key Findings CNS-selective ratio: The proposed marker, brain-derived p-tau217%, estimates the share of circulating tau that is both brain-derived and phosphorylated at …

Read more

Statin Initiation Was Not Linked to Dementia After First Year

by
Statin Initiation Was Not Linked to Dementia After First Year

TL;DR: A 2025 study in Neurology used a Kaiser Permanente target-trial emulation and found that starting a statin was not linked to higher or lower Alzheimer disease or related dementia incidence after the first year. The first-year diagnosis increase likely reflected more medical contact after a new prescription. Key Findings No difference after year one: …

Read more

+ Load more